Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Caroline Apovian MD, FACP, FTOS, DABOM

Caroline M. Apovian MD, FACP, FTOS, DABOM

Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Caroline M. Apovian, MD, is Co-Director of the Center for Weight Management and Wellness (CWMW) in the Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women’s Hospital and a member of the faculty at Harvard Medical School. 

Her current research interests are weight change and its effects on adipose tissue metabolism and inflammation, obesity and cardiovascular disease, resolution of type 2 diabetes and cardiovascular disease in the bariatric surgery population, disparities in the treatment of obesity in underserved populations, and novel pharmacotherapeutic agents for the treatment of obesity. 

Dr. Apovian has published more than 10 books and over 200 peer-reviewed original research and review articles on obesity and nutrition. She has given over 200 invited lectures nationally and internationally and served as President of The Obesity Society in 2017–2018. She is currently the Co-Director for the NIH-funded Boston Nutrition and Obesity Research Center. 

Disclosures

  • Dr. Apovian has participated on advisory boards for Amylin, Merck, Johnson and Johnson, Arena, Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, EnteroMedics, Scientific Intake, Gelesis and Novo Nordisk 
  • Dr. Apovian has received research funding from Lilly, Amylin, Aspire Bariatrics, GI Dynamics, Pfizer, Sanofi-Aventis, Orexigen, MetaProteomics, and the Dr. Robert C. and Veronica Atkins Foundation and MYOS Corporation.
  • Dr. Apovian is currently on the Takeda Speakers Bureau for the medication Contrave.
  • Dr. Apovian has an ownership interest in Science-Smart LLC. 

Recent Contributions to PracticeUpdate:

  1. Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes
  2. Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity
  3. Healthy Weight Loss Maintenance With Exercise + Liraglutide
  4. Overweight in Childhood and Early Adulthood and Risk of Type 2 Diabetes
  5. Obesity: Pathophysiology and Management
  6. Assessment of a Weight Control Program Tailored for Adults With Type 2 Diabetes
  7. Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management Leads to Increased Achievement of Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity
  8. Low–Carbohydrate Diet Scores and Long-Term Risk for T2DM With History of Gestational Diabetes
  9. Healthy Life-Style Habits in Preschool Children
  10. Cardiometabolic Risks and Obesity in Children and Young Adults

Most Read This Week

Recently Updated